Rager's Page

[Rager]

AMZB - Amazon Biotech, Inc. Announces Development of Next-Generation Anti-Viral AIDS Drug Formula
Monday October 9, 6:00 pm ET


Active Ingredients Exhibit -- Immune Modulator Functions and Anti-Viral Properties


NEW YORK, NY--(MARKET WIRE)--Oct 9, 2006 -- Amazon Biotech, Inc. (OTC BB:AMZB.OB - News) (Frankfurt:B2D.F - News) today announced that it has developed a next-generation AIDS formulation which includes both immune modulator functions and anti-viral activity. This formulation, based on Amazon's Phase I/II developmental drug AMZ0026, includes additional active ingredients found in a plant which are known in the literature to posses anti-viral properties.


The entire formulation is comprised of whole plant pharmaceuticals, in line with Amazon Biotech's treatment philosophy. Amazon is now pursuing relevant intellectual property protection and IND (Investigational New Drug application) status from the FDA for this novel formulation. Dr. Mechael Kanovsky, President of Amazon Biotech, said, "We are excited to have reached this stage of development with this promising therapeutic agent."

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company's first such drug, which is to be used for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.

Additional information on Amazon Biotech may be found at: http://www.amazonbiotech.com.

Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof.



Contact:
Contact:
LC Group
Rick Lutz
[phone]



--------------------------------------------------------------------------------
Source: Amazon Biotech, Inc.